Michael Mullan Alzheimers Research

 

The Roskamp Institute is devoted to understanding causes of and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. Based in Sarasota, Florida, the Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease.

Headed by Dr. Michael Mullan, the institute employs experienced and interdisciplinary scientists and technicians and houses state-of-the-art research labs and equipment to conduct scientific research. The quality of research performed at the institute reflects its motto: “Better science. Real discovery.”

 

Michael Mullan is a biomedical researcher of the β-amyloid protein and its relation to Alzheimer’s disease. Mullan’s Alzheimer research is well known among Biomedical Community. Dr. Mullan Alzheimer research work resulted in identifying the most widely known Swiss Mutation that is present in familial form. Transgenic Animal for Alzheimer Disease uses Swiss Mutation.

Dr. Mullan is currently the director[1] of the Roskamp Institute in Sarasota, Florida. Under Dr. Mullan’s guidelines the institute is carrying out cutting edge research in Alzheimer’s, Traumatic Brain Research, Gulf War Illness and other neuropsychiatric disorder.

 

Please visit websites to learn about Dr. Mullan Alzheimer’s Research Website:

 

 

Recent Posts

Antibodies Effectively Treat Alzheimer’s-like Disease

Drs. David Holtzman and Mac Diamond of the Washington University School of Medicine recently published research in Neuron that outlined the process of studying mice for potential tau protein tangle treatment avenues.

Tau is a toxic component of Alzheimer’s and other neurodegenerative diseases, due to the protein’s tendency to amass in tangles.  The aggregates, called neurofibrillary tangles, are believed to interfere with brain function and ultimately lead cognitive decline.  The study followed mice models with a neurodegenerative disease called frontotemporal dementia, whose tau proteins have similar pathology to those present in the brains of Alzheimer’s patients.  The scientists used advanced screening methods to sort through anti-bodies and identify the few that could stop uptake of accumulated tau by cellular interaction, therefore ending intracellular tau tangles.  The researchers then infused three anti-tau antibodies into mice brains.  The results showed mice with the anti-tau antibodies had reduced tau accumulation and increased cognition, while mice infused with control antibodies experienced no change.

The first study to deal with infusing antibodies directly into the brain, Washington University’s research not only suggests a path of action, but solidifies the spread of tau aggregates between cells as a crucial step in tau-mediated diseases like Alzheimer’s.  Dr. Diamond says that their research could lead to the creation of therapies designed to target the aggregation of tau proteins.

Sources:

1) Kiran Yanamandra, Najla Kfoury, Hong Jiang, Thomas E. Mahan, Shengmei Ma, Susan E. Maloney, David F. Wozniak, Marc I. Diamond, David M. Holtzman.  Anti-tau Antibodies Block Tau Aggregates.  September 26, 2013. 10.1016/j.neuron.2013.07.046.

2) Washington University (September 26, 2013). Antibodies Effectively Treat Alzheimer’s-like Disease in Mice. Retrieved October  1, 2013 from http://www.sciencedaily.com/releases/2013/09/130926123326.htm

By Emma Henson

The Roskamp Institute is a 501(c)3 research facility dedicated to translating the efforts of its qualified research staff into real-world results for those suffering from neurological diseases. To learn more about our programs and to get information about donating, visit www.rfdn.org.

  1. ACE Inhibitors and Alzheimer’s Prevention Comments Off
  2. Investigational Therapy Focuses on Slowing Progression in Mild and Moderate Comments Off
  3. A Vicious Cycle of Alzheimer’s and Diabetic Hypoglicemia? Comments Off
  4. A New Drug Reverses Lost Brain Connections in Alzheimer’s Disease Comments Off
  5. Green Tea May Help Prevent Alzheimer’s Disease Comments Off
  6. Alzheimer’s Disease Progression Halted Due to Increased Protein Expression Comments Off
  7. Stem Cells Used to Grow New Neurons, Brain Repair Circuit Identified Comments Off
  8. The Effects of Parkinson’s disease Mutations Reversed within Cells Comments Off
  9. A New Study Shows Small-molecule Drug through Blood-Brain Barrier Comments Off
  10. Antidepressant May Slow Progression of Alzheimer’s Disease Comments Off
  11. Amino Acids Improve Sleep in Mice with Traumatic Brain Injury Comments Off
  12. Controlling length of mitochondria may cure Alzheimer’s diseases Comments Off
  13. Biomarker Could Aid in Revealing Alzheimer’s Early Comments Off
  14. Michael Mullan: Brain Fitness Programs – a scam ? Comments Off
  15. Dr. Michael Mullan Article Published in Herald Tribune: Dr. Michael Mullan: Volunteer to help fight Alzheimer’s Comments Off
  16. Donation Campaign – 36 hour giving challenge campaign Comments Off
  17. Anti-Tumoral Activity of a Short Decapeptide Fragment of the Alzheimer’s Abeta Peptide. Comments Off
  18. Impaired orthotopic glioma growth and vascularization in transgenic mouse models of Alzheimer’s disease. Comments Off
  19. Characterization and use of human brain microvascular endothelial cells to examine β-amyloid exchange in the blood-brain barrier. Bachmeier C, Mullan M, Paris D. Comments Off
  20. Depletion of CXCR2 inhibits γ-secretase activity and amyloid-β production in a murine model of Alzheimer’s disease. Comments Off
  21. Selective antihypertensive dihydropyridines lower Aβ accumulation by targeting both the production and the clearance of Aβ across the blood-brain barrier. Comments Off
  22. Induction of drug efflux protein expression by venlafaxine but not desvenlafaxine. Comments Off
  23. Selective dihydropyiridine compounds facilitate the clearance of β-amyloid across the blood-brain barrier. Comments Off
  24. Feasibility of Predicting MCI/AD Using Neuropsychological Tests and Serum β-Amyloid. Comments Off
  25. Flavonoids lower Alzheimer’s Aβ production via an NFκB dependent mechanism. Comments Off
  26. Roskamp Institute in Sarasota, Florida, have shown that an anatabine compound supplied by Rock Creek has beneficial effects on memory and learning in animal models of Alzheimer’s Disease. Michael Mullan, MD, Ph.D., CEO of the Roskamp Institute and his colleague, Dr. Daniel Paris, published these findings in October, 2011 in the European Journal of Pharmacology Comments Off
  27. Mike Mullan Alzheimer Researcher Comments on: Nicotine May Help Combat Memory Loss study by Dr. Newhouse Comments Off
  28. Identification of Plasma Biomarkers of TBI Outcome Using Proteomic Approaches in an APOE Mouse Model. Comments Off
  29. Anatabine lowers Alzheimer’s Aβ production in vitro and in vivo Comments Off
  30. Elevated CSF levels of TACE activity and soluble TNF receptors in subjects with mild cognitive impairment and patients with Alzheimer’s disease. Comments Off
  31. Genetic deletion of TNF receptor suppresses excitatory synaptic transmission via reducing AMPA receptor synaptic localization in cortical neurons. Comments Off
  32. Proteomic CNS profile of delayed cognitive impairment in mice exposed to gulf war agents. Comments Off
  33. Institute targets in on Alzheimer’s Comments Off
  34. Sarasota’s Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes Comments Off
  35. The Roskamp Institute Comments Off
  36. Roskamp Institute on Gulf War Illness Comments Off
  37. The Roskamp Institute Battles Drug Abuse Comments Off
  38. The Traumatic Brain Injury Program at the Roskamp Institute Comments Off
  39. Roskamp Institute finds one of the genetic causes for Tourettes syndrome Comments Off
  40. Sarasota’s Roskamp Institute Welcomes U.S. Senator Bill Nelson Comments Off
  41. Dr. Mullan’s Alzheimer Research Offers Invaluable Insights On The Disease Comments Off
  42. Dr. Mullan’s Alzheimer Research Identified Various Genetic Variations Comments Off
  43. Family History of Alzheimer’s disease – what does it mean? Comments Off
  44. ß-amyloid exchage in the blood-brain barrier Comments Off
  45. Why work with Alzheimer’s disease patients? Comments Off
  46. Alzheimer’s disease drug developed at Roskamp Institute approved for key clinical trial funding in Europe Comments Off
  47. Roskamp institute studies may lead to better diagnosis Comments Off
  48. Research Highlights The Direct Causes Related To The Disease Comments Off
  49. Dr. Mullan’s Alzheimer Research Involved Studying Brain Proteins Comments Off
  50. Roskamp Institute researchers show that some antibodies but, not others may be helpful in removing the Alzheimer amyloid from the brain of Alzheimer’s sufferers. Comments Off
  51. Mullan Alzheimer Research Institute Roskamp Institute aids high school students in genetic research Comments Off
  52. The Roskamp Institute investigates the role of anatabine in lowering Alzheimer’s Abeta levels. Comments Off
  53. Alzheimer Research Institute Headed By Dr. Michael Mullan Featured in the Sarasota Herald Tribune : Roskamp Institute research could help veterans Comments Off
  54. Dr. Mullan Alzheimer Presentation at Pines of Sarasota Comments Off
  55. Roskamp Institute Celebrated Veterans Day with a seminar by Alzheimer Researcher Dr. Michael Mullan Comments Off
  56. Alzheimer Expert Dr. Mullan’s comments on CD40L induces Abeta production via signaling by the granulocyte macrophage colony stimulating factor (GM-CSF) Comments Off
  57. Alzheimer Researcher Dr. Michael Mullans Note on Potent anti-angiogenic motifs within the Alzheimer beta-amyloid peptide. Comments Off
  58. Effect of NSAIDS on cognitive ability of Alzheimer’s Patient — Comment by Alzheimer Researcher Mullan Comments Off
  59. Dr. Mullan’s Alzheimer Research Notes on NSAIDS and their effect on Alzheimers disease Comments Off
  60. Roskamp Institute Gulf War Illness research program Comments Off
  61. Event: Journal Club “Disrupted-in-Schizophrenia-1 expression is regulated by β-site amyloid precursor protein cleaving enzyme-1–neuregulin cascade” Comments Off
  62. Event: Journal Club “The effect of encapsulated VEGF-secreting cells on brain amyloid load and behavioral impairment in a mouse model of Alzheimer’s disease” Comments Off
  63. News:Nomination for Business/Education Partnership Award through the School District of Manatee County’s ePIE program Comments Off
  64. News:Roskamp Institute was recognized by the South East High School Technical Student association for partnering will the in a diabetes project Comments Off
  65. News: FDA advisory committee unanimously recommends approval of Novartis investigational treatment FTY720 to treat relapsing remitting MS Comments Off
  66. Event: Journal Club “NF-jB activity affects learning in aversive tasks: Possible actions via modulation of the stress axis” Comments Off
  67. News Comments Off
  68. APOLIPOPROTEIN E GENOTYPE AND OXIDATIVE STRESS RESPONSE TO TRAUMATIC BRAIN INJURY Comments Off
  69. Event Journal Club:Amyloid-β and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer’s disease mice Comments Off
  70. Event: Journal Club Comments Off
  71. Announcement Comments Off
  72. News:Dr Crawford will be speaking at 2nd Annual Girls S.T.E.M. Summit Comments Off
  73. Alzheimer’s beta-amyloid peptide blocks vascular endothelial growth factor mediated signaling via direct interaction with VEGFR-2 Comments Off
  74. Tech Tips, #2: Making a homemade frit for fused silica columns Comments Off
  75. Do You Or Someone You Care For Suffer From Alzheimer’s Disease? Comments Off
  76. Reduction of b-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer’s disease Comments Off
  77. NEWS RELEASE:Investigational Immune Intervention Slows Brain Atrophy in Alzheimer’s Patients Comments Off
  78. Journal Club Comments Off
  79. FREE MEMORY SCREENING-Sarasota FL Comments Off
  80. Anti-Tumoral Activity of a Short Decapeptide Fragment of the Alzheimer’s Abeta Peptide Comments Off
  81. Diagnostic utility of APOE, soluble CD40, CD40L, and Abeta1-40 levels in plasma in Alzheimer’s disease Comments Off
  82. CD40/CD40L interaction induces Abeta production and increases gamma-secretase activity independently of tumor necrosis factor receptor associated factor (TRAF) signaling. Comments Off
  83. Roskamp Institute Poster Abstract from VA Reasearch Week Comments Off
  84. Handling Unstructured Data in Biological Research and Clinical Trials Comments Off
  85. Tech Tips: Comments Off
  86. Roskamp Institute is participating in VA Research Week Activities Comments Off
  87. Roskamp Institute-LECOM collaboration Comments Off
  88. High serum Abeta and vascular risk factors in first-degree relatives of Alzheimer’s disease patients Comments Off
  89. Journal Club: The presence of sodium dodecyl sulphate-stable Aβ dimers is strongly associated with Alzheimer-type dementia Comments Off
  90. Alzheimer’s Disease Anti-Inflammatory Prevention Trial Comments Off
  91. Roskamp Institute is at Facebook! Comments Off
  92. Adaptation of the circular platform spatial memory task for mice: use in detecting cognitive impairment in the APPSW transgenic mouse model for Alzheimer’s disease Comments Off
  93. Characteristics of thein VitroVasoactivity of β-Amyloid Peptides Comments Off
  94. Reduction of β-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer’s disease Comments Off
  95. Cross Validation of the Montreal Cognitive Assessment in Community Dwelling Older Adults Residing in the Southeastern US Comments Off
  96. Volunteers for early detection of cognitive decline in older adults Comments Off
  97. Roskamp Institute hosted a town hall meeting for the Alzheimer’s Association. Comments Off
  98. Roskamp Institute Scientist Awarded a grant from the Alzheimers Association to investigate a novel therapeutic agent for the treatment of Alzheimer’s Disease. Comments Off
  99. Roskamp Institute Identifies New Class of Drugs to Treat Alzheimer’s Disease. Comments Off
  100. Roskamp Institute Announces Enrollment of First Students to Participate in its Innovative Research Doctorate Program Comments Off
  101. Southeast High School’s Roskamp Institute project placed first in Florida and fifth in National Technology Students Association finals Comments Off
  102. Local Researchers at Roskamp Institute to Test Investigational Gammaglobulin Treatment for Alzheimer’s Disease Comments Off
  103. World Alzheimer’s Day: Leaders Call for Early Diagnosis and Aggressive Research Comments Off
  104. Dementia in Older Women Comments Off
  105. Alzheimer’s and Blood Pressure Comments Off
  106. What do the names of Barack Obama, Hillary Clinton, and John McCain have to do with Alzheimer’s disease? Comments Off
  107. Double Amyloid Causes Memory Loss Comments Off
  108. First Critical Clinical Tests of the Amyloid Theory of Alzheimer’s Disease Comments Off
  109. Elan Vaccine and Alzheimer’s Disease Drug development Comments Off
  110. Alzheimer’s Disease Drug development Comments Off
  111. Clinical research for Alzheimer’s Disease at the Roskamp Institute Comments Off
  112. DRUG ADDICTION RESEARCH AT THE ROSKAMP INSTITUTE Comments Off
  113. Traumatic Brain Injury in the War Zone Comments Off
  114. Research On Traumatic Brain Injury At The Roskamp Institute Comments Off
  115. ABeta as Antiangiogenic drug Comments Off
  116. Roskamp Institute examines the cellular responses to biological warfare agents Comments Off
  117. Clinical Trials for Alzheimer’s Disease at the Roskamp Institute Comments Off
  118. Press release for James & Esther King Biomedical Research Program grant Comments Off
  119. Genetic manipulation of CD40L reduces Tau phosphorylation Comments Off
  120. The granulocyte macrophage-colony stimulating factor (GM-CSF) regulates amyloid production Comments Off
  121. Potent antiangiogenic motif in amyloid beta Comments Off
  122. CD40L induces Abeta production via signaling by the granulocyte macrophage colony stimulating factor (GM-CSF) Comments Off
  123. Potent anti-angiogenic motifs within the Alzheimer beta-amyloid peptide Comments Off
  124. Effect of NSAIDS on cognitive ability of Alzheimer’s Patients Comments Off
  125. NSAIDS and their effect on Alzheimers disease Comments Off
  126. Roskamp Institute is Part of a Great Technology Cluster Comments Off
  127. Roskamp Institute Receives Lung Cancer Research Grant Comments Off
  128. Roskamp Institute Recognized for Its Beautification Efforts Comments Off
  129. Roskamp Institute Helps Florida’s Economy Comments Off
  130. Roskamp Institute Supports Moves for Greater State Funding of Biotech Research Comments Off
  131. Roskamp Institute Looking for Alzheimer’s Clinical Trial Participants Comments Off
  132. The Roskamp Institute Plans Alzheimer’s Treatment Trial Comments Off
  133. Roskamp’s Fiona Crawford to Participate in Panel Discussion Comments Off
  134. Roskamp Institute Will Host Neuroscience Doctorate Research Program Comments Off
  135. Roskamp Institute Alzheimer’s Research Validated by Independent Japanese Study Comments Off
  136. Roskamp Institute Receives Award of Appreciation Comments Off
  137. Roskamp Institute Studying Potential Usefulness of Beta-amyloid in Treating Alzheimer’s Comments Off
  138. Nilvadipine an anti-hypertensive drug, as a potential treatment for Alzheimer’s disease Comments Off
  139. Anti-hypertension Drugs and Alzheimers Comments Off
  140. Roskamp Institute’s Fiona Crawford to Moderate at Power of Women Series Comments Off
  141. Conscientious people are less prone to Alzheimer’s Comments Off
  142. The Traumatic Brain Injury Program at the Roskamp Institute Comments Off
  143. Sarasota’s Roskamp Institute Welcomes U.S. Senator Bill Nelson Comments Off
  144. Senator Nelson Visit Roskamp Institute Comments Off
  145. Roskamp Institute Aims to Help Injured Soldiers Comments Off
  146. British Experts Question Need for Baby Scans Comments Off
  147. Chromosomes Shed New Light on Down Syndrome Comments Off
  148. Down Syndrome Patient Learning New Skills Comments Off
  149. Novartis Required to Correct Advertising Comments Off
  150. Tracking Wandering Alzheimer’s Sufferers Comments Off
  151. Alzheimer’s Caregiver Training Comments Off
  152. Attending College with Intellectual Disabilities Comments Off
  153. National Down Syndrome Society Comments Off
  154. Alzheimer’s Widow to Serve as British Government Adviser Comments Off
  155. Alzheimer’s Disease Disscusion Forum Comments Off
  156. The Roskamp Institute Is Good for Manatee County, Florida Comments Off
  157. Roskamp Institute Obesity and Diabetes Study Official Release Comments Off
  158. Roskamp Institute Study Examines Obesity Comments Off
  159. Clinical Trial Information Comments Off
  160. Sarkozy Vows to Defeat Alzheimer’s Comments Off
  161. Study: Spice can help Alzheimer’s Patients Comments Off
  162. Want a job in science research? Comments Off
  163. Roskamp Institute Tries to Improve Life of Alzheimer’s Suffers Comments Off
  164. Neuropsychology Comments Off
  165. Study: Alzheimer’s Cases May Quadruple by 2050 Comments Off
  166. Alzheimer’s Support Groups Comments Off
  167. Roskamp Celebrated 2006 World Alzheimer’s Day with Clinical Trial Lauch Comments Off
  168. Good News for Alzheimer’s Drug Comments Off
  169. Roskamp Institute Announces New Treatment Comments Off
  170. Roskamp Institute Media Coverage Comments Off
  171. The Roskamp Institute is Participating in a New Phase III MS Study Comments Off
  172. Michael Mullan Featured in Another Story Comments Off
  173. Roskamp’s Michael Mullan Interviewed by St. Petersburg Times Comments Off
  174. Sarasota’s Roskamp Institute Announces Participation in Multiple Sclerosis Study Comments Off
  175. Roskamp Institute recruiting for clinical trials Comments Off
  176. Roskamp Institute Announces New Class Of Drugs That Can Impact Alzheimer’s Disease Comments Off